RxDoctor Payments DataLook up a doctor →

Martha Gomez, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1003822651

Payments from drug & device makers

$3,768,351in general payments, 2019–2025

Across 450 payments — averaging $8374.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$3.7M
  • Eli Lilly$101K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novo Nordisk$1K
  • plus $2K from 9 others
$1,427,351in research payments, 2019–2025

Across 31 payments — averaging $46,044 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$1.1M
  • Eli Lilly$288K

What the payments were for

  • Speaking & faculty fees$3003%
  • Travel & lodging$3,22627%
  • Food & beverage$8,45170%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,768,351 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,105
Medicare patients
40
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin355$279,932
OzempicSemaglutide204$203,955
TrulicityDulaglutide145$183,788
Synjardy XrEmpagliflozin/Metformin Hcl182$127,350
SynthroidLevothyroxine Sodium1,090$95,459
JanuviaSitagliptin Phosphate120$95,242
MounjaroTirzepatide79$90,679
FarxigaDapagliflozin Propanediol79$69,300
Xigduo XrDapaglifloz Propaned/Metformin84$59,577
ProliaDenosumab32$56,034
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog79$52,941
RybelsusSemaglutide48$52,302
SynjardyEmpagliflozin/Metformin Hcl95$35,915
Humalog Kwikpen U-200Insulin Lispro28$25,405
Janumet XrSitagliptin Phos/Metformin Hcl14$23,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta$1,450$463,514659 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25, Humalog, Humulin 70-30$106$300,800402 claims
Novo NordiskOzempic, Rybelsus$1,165$256,257252 claims
MerckJanuvia, Janumet Xr, Janumet$591$134,320156 claims
AbbVieSynthroid$181$95,4591,090 claims
AstraZenecaFarxiga$1,518$69,30079 claims
AmgenProlia$35$56,03432 claims
Sanofi-aventis U.S. LLCLantus$1,373$13,394126 claims
Johnson & JohnsonXarelto$415$8,55915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →